PatientsVille.com Logo

Quadramet Side Effects

PatientsVille

Common Quadramet Side Effects


The most commonly reported Quadramet side effects (click to view or check a box to report):

Pain (15)
Thrombocytopenia (13)
Condition Aggravated (12)
Disease Progression (12)
Nausea (9)
Back Pain (8)
Blood Creatinine Increased (7)
Malignant Neoplasm Progression (7)
Haemoglobin Decreased (7)
Arthralgia (6)
Atrial Fibrillation (6)
Haematuria (6)
Dyspnoea (6)
Anorexia (5)
Acute Pulmonary Oedema (5)
Pain In Extremity (5)
Pancytopenia (5)
Platelet Count Decreased (5)
Anxiety (5)
Cardiac Failure Congestive (4)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Quadramet Side Effects Reported to FDA



Quadramet Side Effect Report#9413310
Cardiac Arrest
This is a report of a 58-year-old male patient (weight: NA) from US, suffering from the following health symptoms/conditions: prostate cancer, who was treated with Quadramet (dosage: (124 Mci (124 Mci), start time:
Jan 18, 2012), combined with: NA. and developed a serious reaction and side effect(s): Cardiac Arrest after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in Cardiac Arrest side effect.
Quadramet Side Effect Report#9189716
Platelet Count Decreased, Neutrophil Count Decreased
This report suggests a potential Quadramet Platelet Count Decreased side effect(s) that can have serious consequences. A 66-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: prostate cancer and used Quadramet (dosage: NA) starting
Dec 19, 2012. After starting Quadramet the patient began experiencing various side effects, including: Platelet Count Decreased, Neutrophil Count DecreasedAdditional drugs used concurrently: NA. Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Platelet Count Decreased, may still occur.
Quadramet Side Effect Report#8848766
Thrombocytopenia, Prostate Cancer
This Thrombocytopenia problem was reported by a health professional from AU. A 64-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: prostate cancer. On NS this consumer started treatment with Quadramet (dosage: 1.5 Gy X2, Intravenous (not Otherwise Specified)). The following drugs were being taken at the same time: NA. When using Quadramet, the patient experienced the following unwanted symptoms/side effects: Thrombocytopenia, Prostate CancerAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Thrombocytopenia, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#8848758
Thrombocytopenia, Prostate Cancer
This Thrombocytopenia side effect was reported by a health professional from AU. A 71-year-old male patient (weight:NA) experienced the following symptoms/conditions: prostate cancer.The patient was prescribed Quadramet (drug dosage: 1.5 Gy X 2 , Intravenous (not Otherwise Specified)), which was initiated on NS. Concurrently used drugs: NA..After starting to take Quadramet the consumer reported adverse symptoms, such as: Thrombocytopenia, Prostate CancerThese side effects may potentially be related to Quadramet.
Quadramet Side Effect Report#8847159
Thrombocytopenia
This is a report of a 69-year-old male patient (weight: NA) from US, suffering from the following health symptoms/conditions: prostate cancer, who was treated with Quadramet (dosage: NA, start time: NS), combined with: NA. and developed a serious reaction and side effect(s): Thrombocytopenia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in Thrombocytopenia side effect.
Quadramet Side Effect Report#7535638-6
Pancytopenia, Neoplasm Progression, Bone Sarcoma
This report suggests a potential Quadramet Pancytopenia side effect(s) that can have serious consequences. A 19-year-old female patient (weight: NA) from was diagnosed with the following symptoms/conditions: bone sarcoma and used Quadramet (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)) starting NS. After starting Quadramet the patient began experiencing various side effects, including: Pancytopenia, Neoplasm Progression, Bone SarcomaAdditional drugs used concurrently:
  • 18f-fdg (fludeoxyglucose)
  • Contrast Media (contrast Media)
Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Pancytopenia, may still occur.
Quadramet Side Effect Report#7535637-4
Pancytopenia, Bone Sarcoma, Neoplasm Progression
This Pancytopenia problem was reported by a physician from . A 14-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: bone sarcoma. On NS this consumer started treatment with Quadramet (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)). The following drugs were being taken at the same time:
  • Contrast Media (contrast Media)
  • 18f-fdg (fludeoxyglucose (18f))
When using Quadramet, the patient experienced the following unwanted symptoms/side effects: Pancytopenia, Bone Sarcoma, Neoplasm ProgressionAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Pancytopenia, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#7535605-2
Bone Sarcoma, Disease Progression, Pancytopenia
This Bone Sarcoma side effect was reported by a physician from . A 17-year-old male patient (weight:NA) experienced the following symptoms/conditions: bone sarcoma.The patient was prescribed Quadramet (drug dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)), which was initiated on NS. Concurrently used drugs:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media (contrast Media)
.After starting to take Quadramet the consumer reported adverse symptoms, such as: Bone Sarcoma, Disease Progression, PancytopeniaThese side effects may potentially be related to Quadramet.
Quadramet Side Effect Report#7535602-7
Pleural Effusion, Dyspnoea, Disease Progression, Pancytopenia
This is a report of a 30-year-old female patient (weight: NA) from , suffering from the following health symptoms/conditions: NA, who was treated with Quadramet (dosage: 1.2 Mci/kg, Intravenous, start time:
Dec 16, 2005), combined with:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media (contrast Media)
and developed a serious reaction and side effect(s): Pleural Effusion, Dyspnoea, Disease Progression, Pancytopenia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in female patients, resulting in Pleural Effusion side effect.
Quadramet Side Effect Report#7313257-4
Thrombocytopenia, Renal Failure Acute, Femur Fracture, Malaise, Fatigue, Obstruction
This report suggests a potential Quadramet Thrombocytopenia side effect(s) that can have serious consequences. A male patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: NA and used Quadramet (dosage: 86.9 Mci) starting NS. After starting Quadramet the patient began experiencing various side effects, including: Thrombocytopenia, Renal Failure Acute, Femur Fracture, Malaise, Fatigue, ObstructionAdditional drugs used concurrently:
  • Lotrel
  • Vitamin D (400 Iu)
  • Calcium Carbonate (600 Mg)
  • Zometa (4 Mg)
  • Simvastatin
  • Levothroid
  • Aspirin
The patient was hospitalized. Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Thrombocytopenia, may still occur.
Quadramet Side Effect Report#7208243-9
Malignant Neoplasm Progression, Osteosarcoma Metastatic, Pancytopenia
This Malignant Neoplasm Progression problem was reported by a physician from United States. A 18-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: bone sarcoma. On NS this consumer started treatment with Quadramet (samarium (153 Gm) Lexidronam) (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)). The following drugs were being taken at the same time:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media(contrast Media)
When using Quadramet (samarium (153 Gm) Lexidronam), the patient experienced the following unwanted symptoms/side effects: Malignant Neoplasm Progression, Osteosarcoma Metastatic, PancytopeniaAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Malignant Neoplasm Progression, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#7206076-0
Metastases To Central Nervous System
This Metastases To Central Nervous System side effect was reported by a consumer or non-health professional from United States. A female patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Quadramet (drug dosage: .94 Ml), which was initiated on NS. Concurrently used drugs:
  • Zometa (4 Mg)
  • Vitamin D2 (3600 Million Iu)
.After starting to take Quadramet the consumer reported adverse symptoms, such as: Metastases To Central Nervous SystemThese side effects may potentially be related to Quadramet. The patient was hospitalized.
Quadramet Side Effect Report#7203479-5
Metastases To Central Nervous System
This is a report of a female patient (weight: NA) from United States, suffering from the following health symptoms/conditions: NA, who was treated with Quadramet (dosage: .94 Ml, start time: NS), combined with:
  • Zometa (4 Mg)
  • Vitamin D2 (3600 Million Iu)
and developed a serious reaction and side effect(s): Metastases To Central Nervous System after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in female patients, resulting in Metastases To Central Nervous System side effect. The patient was hospitalized.
Quadramet Side Effect Report#7104590-X
Pneumonia
This report suggests a potential Quadramet Pneumonia side effect(s) that can have serious consequences. A 62-year-old female patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: palliative care and used Quadramet (dosage: 50 Mci At A Dose Of 1 Mcg/kg, Intravenous) starting
Oct 20, 2010. After starting Quadramet the patient began experiencing various side effects, including: PneumoniaAdditional drugs used concurrently:
  • Docusate (docusate)
  • Zoledronic Acid
Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Pneumonia, may still occur.
Quadramet Side Effect Report#6657119-4
Atelectasis, Culture Urine Positive, Diarrhoea, Pyrexia, White Blood Cell Count Decreased
This Atelectasis problem was reported by a physician from United States. A 74-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: prostate cancer metastatic. On
Aug 27, 2008 this consumer started treatment with Quadramet (dosage: 1.0 Mci/kg, Intravenous). The following drugs were being taken at the same time:
  • Docetaxel (3.5714 Mg/m2, 1 In 3 Weeks, Intravenous)
  • Zoledronic Acid
  • Lupron
  • Decadron
  • Prednisone Tab
  • Oxycodone Hcl
  • Meloxicam
  • Ibuprofen
When using Quadramet, the patient experienced the following unwanted symptoms/side effects: Atelectasis, Culture Urine Positive, Diarrhoea, Pyrexia, White Blood Cell Count DecreasedThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Atelectasis, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#6597222-0
Activities Of Daily Living Impaired, Blood Creatine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haematocrit Decreased, Haemoglobin Decreased, Lymphocyte Percentage Decreased
This Activities Of Daily Living Impaired side effect was reported by a health professional from United States. A 57-year-old female patient (weight:NA) experienced the following symptoms/conditions: metastases to bone.The patient was prescribed Quadramet (drug dosage: Intravenous), which was initiated on
Jan 21, 2010. Concurrently used drugs:
  • Cymbalta (Enteric Coated, 1 Po Bid, Oral)
  • Lorazepam (1 Po Q4h Prn, Oral)
  • Morphine Sulfate (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral)
  • Morphine Sulfate (Sustained Action, 1 Po O12h, Oral)
  • Ambien Cr, Po Solid Sr (zolpidem Tartrate) (tablets)
  • Azor, Po Solid (amlodipine) (tablets)
  • Caltrate 600+d Plus, Po Solid (calcite D) (tablets)
  • Femara, Po Solid (letrozole) (tablets)
.After starting to take Quadramet the consumer reported adverse symptoms, such as: Activities Of Daily Living Impaired, Blood Creatine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haematocrit Decreased, Haemoglobin Decreased, Lymphocyte Percentage DecreasedThese side effects may potentially be related to Quadramet.
Quadramet Side Effect Report#6595771-2
Blood Creatinine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haemoglobin Decreased, Lymphocyte Percentage Decreased, Mean Platelet Volume Decreased
This is a report of a 57-year-old female patient (weight: NA) from United States, suffering from the following health symptoms/conditions: bone pain, who was treated with Quadramet (dosage: Intravenous, start time:
Jan 21, 2010), combined with:
  • Cymbalta (Enteric Coated, 1 Po Bid, Oral)
  • Lorazepam (1 Po Q4h Prn, Oral)
  • Morphine Sulfate (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral)
  • Morphine Sul Hyt (Sustained Action, 1 Po Q12h, Oral)
  • Ambien Cr, Po Solid Sr (zolpidem Tartrate)(tablets)
  • Azor, Po Solid (amlodipine)(tablets)
  • Caltrate 600+d Plus, Po Solid (calcite D)(tablets)
  • Femara, Po Solid (letrozole) (tablets)
and developed a serious reaction and side effect(s): Blood Creatinine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haemoglobin Decreased, Lymphocyte Percentage Decreased, Mean Platelet Volume Decreased after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in female patients, resulting in Blood Creatinine Increased side effect.
Quadramet Side Effect Report#5951231-0
Platelet Count Decreased
This report suggests a potential Quadramet Platelet Count Decreased side effect(s) that can have serious consequences. A 56-year-old male patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: prostate cancer and used Quadramet (dosage: 135 Mci Iv Injection) starting
Mar 20, 2008. After starting Quadramet the patient began experiencing various side effects, including: Platelet Count DecreasedAdditional drugs used concurrently:
  • ..
  • Zoladex
  • Casodex
Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Platelet Count Decreased, may still occur.
Quadramet Side Effect Report#5877997-6
Bloody Discharge, Body Temperature Increased, Disease Progression, Hydronephrosis, Hypotension, Lung Disorder, Lymphadenopathy, Mediastinal Disorder, Neutropenia
This Bloody Discharge problem was reported by a consumer or non-health professional from United States. A male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Quadramet (dosage: 99.7 Mci). The following drugs were being taken at the same time:
  • Zometa (25.3 Mg)
  • Lupron + Casodex
  • Mitoxantrone + Prednisone
When using Quadramet, the patient experienced the following unwanted symptoms/side effects: Bloody Discharge, Body Temperature Increased, Disease Progression, Hydronephrosis, Hypotension, Lung Disorder, Lymphadenopathy, Mediastinal Disorder, NeutropeniaThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Bloody Discharge, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#5780028-X
No Adverse Event
This No Adverse Event side effect was reported by a health professional from United States. A 65-year-old male patient (weight:NA) experienced the following symptoms/conditions: bone pain.The patient was prescribed Quadramet (drug dosage: NA), which was initiated on NS. Concurrently used drugs: NA..After starting to take Quadramet the consumer reported adverse symptoms, such as: No Adverse EventThese side effects may potentially be related to Quadramet.
Quadramet Side Effect Report#5777411-5
Asthenia, Dyskinesia, Toxic Encephalopathy
This is a report of a 70-year-old male patient (weight: NA) from United States, suffering from the following health symptoms/conditions: bone pain, who was treated with Quadramet (dosage: NA, start time: NS), combined with: NA. and developed a serious reaction and side effect(s): Asthenia, Dyskinesia, Toxic Encephalopathy after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in Asthenia side effect. The patient was hospitalized.
Quadramet Side Effect Report#5535723-4
Dehydration, Duodenal Ulcer, Obstruction Gastric, Reflux Oesophagitis, Urinary Tract Infection
This report suggests a potential Quadramet Dehydration side effect(s) that can have serious consequences. A male patient (weight: NA) from United States was diagnosed with the following symptoms/conditions: NA and used Quadramet (dosage: Received Only One Dose Per The Protocol On 6/27/2007) starting
Jun 27, 2007. After starting Quadramet the patient began experiencing various side effects, including: Dehydration, Duodenal Ulcer, Obstruction Gastric, Reflux Oesophagitis, Urinary Tract InfectionAdditional drugs used concurrently:
  • Vitamin D (2800 Iu Took 2800 Iu Total For This Course (400iu Per Day) But Started In May Of 2007 With Course 1)
  • Zometa (4 Mg)
The patient was hospitalized. Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Dehydration, may still occur.
Quadramet Side Effect Report#5483824-1
Syncope
This Syncope problem was reported by a consumer or non-health professional from United States. A female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Quadramet (dosage: 69.5 Mg). The following drugs were being taken at the same time:
  • Zometa (4 Mg)
  • Calcium
  • Vitamin D
  • Levothyroxine Sodium
When using Quadramet, the patient experienced the following unwanted symptoms/side effects: SyncopeThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Syncope, may become evident only after a product is in use by the general population.
Quadramet Side Effect Report#5352560-4
Agitation, Burning Sensation, Dermatitis Allergic
This Agitation side effect was reported by a health professional from United States. A 57-year-old female patient (weight:NA) experienced the following symptoms/conditions: palliative care.The patient was prescribed Quadramet (drug dosage: 176 Gbq), which was initiated on
Dec 20, 2006. Concurrently used drugs:
  • Morphine
  • Neurontin
  • Nexiam (esomeprazole)
  • Voltaren
  • Serotonin Antagonists
.After starting to take Quadramet the consumer reported adverse symptoms, such as: Agitation, Burning Sensation, Dermatitis AllergicThese side effects may potentially be related to Quadramet. The patient was hospitalized.
Quadramet Side Effect Report#5352524-0
Metastases To Abdominal Cavity, Pain, Thrombocytopenia
This is a report of a 78-year-old male patient (weight: NA) from United States, suffering from the following health symptoms/conditions: metastases to bone, who was treated with Quadramet (dosage: 1 Mci/kg, 37mbq/kg 1 Dose, Intravenous, start time: NS), combined with:
  • Technetium Tc 99m Methylene Diphosphonate
and developed a serious reaction and side effect(s): Metastases To Abdominal Cavity, Pain, Thrombocytopenia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in Metastases To Abdominal Cavity side effect.

1 of 4 


The appearance of Quadramet on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.


Track Your Side Effects

Note Your Observations

It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    Quadramet reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
    FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

    Discuss Quadramet Side Effects

    Did You Have a Quadramet Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Quadramet for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Quadramet Safety Alerts, Active Ingredients, Usage Information

    NDC11994-016
    TypeHUMAN PRESCRIPTION DRUG
    Proprietary NameQuadramet
    NameSamarium SM 153 Lexidronam
    Dosage FormINJECTION, SOLUTION
    RouteINTRAVENOUS
    On market since19970519
    LabelerLantheus Medical Imaging, Inc.
    Active Ingredient(s)SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
    Strength(s)50
    Unit(s)mCi/mL
    Pharma Class

    Quadramet Dosage, Warnings, Usage.

    Side Effects reported to FDA: 80

    Quadramet safety alerts: No

    Reported deaths: 23

    Reported hospitalizations: 69

    Latest Quadramet clinical trials

    Quadramet Reviews

    No reviews, be a first to report a side effect via side effect reporting form